Quarterly report pursuant to Section 13 or 15(d)

Pro Forma Condensed Consolidated Statements of Comprehensive Loss (Unaudited)

v3.21.1
Pro Forma Condensed Consolidated Statements of Comprehensive Loss (Unaudited)
 3 Months Ended
Mar. 31, 2021
USD ($)
$ / shares
shares
Product Revenue
Product Cost of Sales
Gross Income
Operating Expenses:  
Administrative Expenses 1,508,336
Sales and Marketing Expenses
Research and Development Expenses (19,365)
Loss from Operations (1,488,971)
Other (Income) Expenses  
(Gain)/Loss on Investments (12,649)
Loss on Fair Market Value of Equity Investments 14,402
Total Other Income (41,700)
Loss from Continuing Operations Before Income Tax (1,447,271)
Income Tax Benefit
Loss from Continuing Operations $ (1,447,271)
Basic and Diluted loss per common share from continuing operations | $ / shares $ (0.17)
Weighted average basic common shares outstanding | shares 8,544,298
Pro Forma [Member]  
Product Revenue
Product Cost of Sales
Gross Income
Operating Expenses:  
Administrative Expenses 2,755,584
Sales and Marketing Expenses
Research and Development Expenses 1,042,926
Total operating expenses 3,798,510
Loss from Operations (3,798,510)
Other (Income) Expenses  
Loss on Disposal of Property and Equipment
Foreign Currency Transaction Loss
(Gain)/Loss on Investments (12,649)
Loss on Fair Market Value of Equity Investments 14,402
Interest and Dividend (Income)/Expense 643,248
Total Other Income 65,401
Loss from Continuing Operations Before Income Tax (4,443,511)
Income Tax Benefit
Loss from Continuing Operations $ (4,443,511)
Basic and Diluted loss per common share from continuing operations | $ / shares $ (0.12)
Weighted average basic common shares outstanding | shares 37,500,088 [1]
Cystron Biotech Spin-Off Adjustments [Member]  
Product Revenue
Product Cost of Sales
Gross Income
Operating Expenses:  
Administrative Expenses
Sales and Marketing Expenses
Research and Development Expenses 10,290
Total operating expenses 10,290
Loss from Operations (10,290)
Other (Income) Expenses  
Loss on Disposal of Property and Equipment
Foreign Currency Transaction Loss
(Gain)/Loss on Investments
Loss on Fair Market Value of Equity Investments
Interest and Dividend (Income)/Expense
Total Other Income
Loss from Continuing Operations Before Income Tax (10,290)
Income Tax Benefit
Loss from Continuing Operations (10,290)
Adjustments [Member]  
Product Revenue
Product Cost of Sales
Gross Income
Operating Expenses:  
Administrative Expenses 979,757
Sales and Marketing Expenses
Research and Development Expenses
Total operating expenses 979,757
Loss from Operations (979,757)
Other (Income) Expenses  
Loss on Disposal of Property and Equipment
Foreign Currency Transaction Loss
(Gain)/Loss on Investments
Loss on Fair Market Value of Equity Investments
Interest and Dividend (Income)/Expense 26,137
Total Other Income 26,137
Loss from Continuing Operations Before Income Tax (26,137)
Income Tax Benefit
Loss from Continuing Operations $ (26,137)
Weighted average basic common shares outstanding | shares 28,955,790
Legal Acquirer Akers [Member] | Pro Forma [Member]  
Product Revenue
Product Cost of Sales
Gross Income
Operating Expenses:  
Administrative Expenses 1,508,336
Sales and Marketing Expenses
Research and Development Expenses (19,365)
Total operating expenses 1,488,971
Loss from Operations (1,488,971)
Other (Income) Expenses  
Loss on Disposal of Property and Equipment
Foreign Currency Transaction Loss
(Gain)/Loss on Investments (12,649)
Loss on Fair Market Value of Equity Investments 14,402
Interest and Dividend (Income)/Expense (43,453)
Total Other Income (41,700)
Loss from Continuing Operations Before Income Tax (1,447,271)
Income Tax Benefit
Loss from Continuing Operations $ (1,447,271)
Basic and Diluted loss per common share from continuing operations | $ / shares $ (0.17)
Weighted average basic common shares outstanding | shares 8,544,298
Accounting Acquirer MyMD [Member] | Pro Forma [Member]  
Product Revenue
Product Cost of Sales
Gross Income
Operating Expenses:  
Administrative Expenses 1,247,248
Sales and Marketing Expenses
Research and Development Expenses 1,052,001
Total operating expenses 2,299,249
Loss from Operations (2,299,249)
Other (Income) Expenses  
Loss on Disposal of Property and Equipment
Foreign Currency Transaction Loss
(Gain)/Loss on Investments
Loss on Fair Market Value of Equity Investments
Interest and Dividend (Income)/Expense 660,564
Total Other Income 660,564
Loss from Continuing Operations Before Income Tax 2,959,813
Income Tax Benefit
Loss from Continuing Operations $ (2,959,813)
[1] All outstanding stock options, Series D convertible preferred stock and pre-funded warrants exercisable for the combined company's common stock are anti-dilutive and therefore excluded from the weighted-average shares calculation for the three months ended March 31, 2021 as referenced in the pro forma condensed combined Statement of Comprehensive Loss.